



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Road,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Launch of LAIV Flu vaccine in China

Melbourne, 25 August 2020: Australian vaccine development company BioDiem Ltd (“BioDiem” or the “Company”) is pleased to announce the product launch of Changchun BCHT Biotechnology Co (BCHT)’s LAIV vaccine in China. This is a major milestone for BCHT and for BioDiem. BCHT is BioDiem’s licensee for the LAIV flu vaccine technology in China.

BCHT has advised that it will hold a special function to celebrate the first vaccination using its new “Influenza Vaccine, Live, Nasal, Freeze-dried” product this week. The ceremony will take place in Zhengzhou, the capital of Henan Province in the middle of China.

BCHT’s intranasal seasonal flu vaccine is based on the World Health Organization’s recommendations for the 2020-2021 ‘flu season. BCHT gained marketing approval for its LAIV vaccine from the Chinese National Medical Products Administration (formerly known as the Chinese FDA) in February this year.

Dr. Kong Wei, the CEO of Changchun BCHT Biotechnology Co., China said "This is the first needle-free, intranasal and homebred influenza vaccine launched in China. I hope that with its effectiveness and acceptability, the vaccine will help prevent more people getting influenza infection giving them a healthier life, especially under the current circumstance of the COVID-19 pandemic."

BCHT has a dedicated team of vaccine development specialists behind the successful development of the LAIV flu vaccine and BCHT’s other vaccine products including rabies and varicella. Following the launch, BCHT will use its strong distributor network which covers all provinces and municipalities in mainland China, except Tibet.

BioDiem’s CEO, Julie Phillips said, “We heartily congratulate BCHT on this major product launch and recognise the significant effort of the BCHT team to get to this achievement. The value of a vaccine in preventing a highly contagious infectious disease is recognised now more than ever.” BioDiem will receive royalties from the sale of BCHT’s influenza vaccine product in the China private sector market with a minimum payment.

The LAIV flu vaccine technology platform originated from the Institute of Experimental Medicine in St Petersburg, Russia. The career-long dedication to the development of this needle-free vaccine by Prof Larisa Rudenko and her Russian team was recognised in a special feature in *The Lancet, Infectious Diseases* in June 2020¹. It highlights their work in not just seasonal flu but also pandemic flu vaccines, and has gained support from many international public health agencies. Prof Rudenko is a director of BioDiem Ltd.

China-based BCHT holds an exclusive licence from BioDiem for the influenza technology based on the live attenuated influenza virus (LAIV) vaccine technology. BCHT’s licence covers the private sector market of China for pandemic and seasonal influenza vaccines made using an egg-based production method. BCHT holds a complementary licence to the LAIV for the public market in China via a sublicense from the World Health Organisation.

¹ [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30391-1/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30391-1/fulltext)

Share trading information

BioDiem Ltd is a public unlisted company. A register of interest for share trading is maintained by Leydin Freyer where buyers and sellers are encouraged to notify their trading interest. The EOFY20 valuation of BioDiem preference and ordinary shares was \$0.08 (8 cents).

Shareholder Information at Share Registry, Computershare.

Shareholders are asked to ensure their contact details/email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre (www.computershare.com.au).

- ENDS -

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income is from licence fees and royalties on sales.

BioDiem's technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. BioDiem has licensed the LAIV to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply and to two commercial partners, in India and China:

- Serum Institute of India's Nasovac-S™ is marketed in India; and
- Changchun BCHO Biotechnology is launching its "Influenza Vaccine, Live, Nasal, Freeze-dried" vaccine in China in August 2020.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit www.biodiem.com.

Further information

Julie Phillips, Chief Executive Officer, BioDiem Ltd

Phone +61 3 9692 7222

Email jphillips@biodiem.com

Twitter @biodiem @opalbiosciences